Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Holders of 5% or more of GLUE
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Monte Rosa Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 13G/A | 10.50%8.86M shares | +3.00 ppfrom 7.50% | Feb 10, 20228 filings | Jul 8, 2026 | SEC |
| Baker Bros. Advisors LP | 13G/A | 9.99%8.88M shares | +3.29 ppfrom 6.70% | Feb 14, 20243 filings | May 15, 2026 | SEC |
| Dimension Capital I, L.P. | 13G/A | 8.10%6.51M shares | −0.60 ppfrom 8.70% | Oct 3, 20253 filings | Apr 22, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D/A | 7.90%6.69M shares | −1.80 ppfrom 9.70% | Jul 12, 20215 filings | Jul 6, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 6.30%5.09M shares | +0.40 ppfrom 5.90% | Jan 31, 20254 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G | 6.30%3.84M shares | New | Feb 4, 20251 filing | Feb 4, 2025 | SEC |
| TCG Crossover GP II, LLC | 13G/A | 5.50%4.62M shares | −1.70 ppfrom 7.20% | Oct 17, 20252 filings | May 15, 2026 | SEC |
| Vestal Point Capital, LP | 13G | 5.40%4.60M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
58 Schedule 13D and 13G filings on Monte Rosa Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 10, 2022 | Price T Rowe Associates Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 20225:22 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Aug 10, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
| Jul 12, 2021 | New Enterprise Associates 17, L.P. | 13DOld format | – | New | – | SEC |
| Jul 8, 2021 | Versant Venture Capital VI, L.P. | 13DOld format | – | New | – | SEC |
| Jul 8, 2021 | Cormorant Asset Management, LP | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
4 notices from officers, directors and other affiliates planning to sell Monte Rosa Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Oct 28, 20244:05 PM ET | Wallace Owen B.Officer | 20.0K | $240.0K | Oct 28, 202410b5-1 | UBS Financial Services Inc. | SEC |
| May 1, 20244:26 PM ET | Jones Jullian GOfficer | 105.1K | $559.0K | May 1, 2024 | Jefferies LLC | SEC |
| Apr 10, 20244:24 PM ET | Jones Jullian GOfficer | 103.5K | $813.9K | Apr 10, 2024 | Jefferies LLC | SEC |
| Aug 15, 20235:16 PM ET | Tamboli AjimRecently departed CFO | 411.9K | $2.68M | Aug 15, 2023 | Morgan Stanley Smith Barney LLC | SEC |